The Department of Justice scored its biggest healthcare fraud settlement yet on July 2 when GlaxoSmithKline agreed to pay $3 billion for promoting off-label uses of its Paxil and Wellbutrin antidepressants and for holding back safety data from the Food and Drug Administration about its Avandia diabetes drug. The previous record-holder was Pfizer, which in 2009
GlaxoSmithKline Settles for $3 Billion
The pharma company’s $3 billion settlement on improper drug promotions and misbranding charges is the largest yet for the drug industry.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments
